Dual-antiplatelet therapy (DAPT) prevents thrombotic complications associated with
coronary artery disease, acute coronary syndrome, and stent thrombosis following the …

BACKGROUND: Dual antiplatelet therapy (DAPT) has been found to reduce the risk of
cardiac death, myocardial infarction, stroke, and stent thrombosis following acute coronary …

Background: Proton pump inhibitors (PPIs) are used to prevent gastrointestinal hemorrhage
in patients with coronary treatment undergoing dual antiplatelet therapy (DAPT). Methods: A …

Background: The safety and efficacy associated with the use of proton pump inhibitors (PPIs)
by patients with coronary artery disease receiving dual antiplatelet therapy (DAPT) remain …

Objective Dual antiplatelet therapy reduces the risk of ischemic complications after acute
coronary syndrome, but increases the risk of bleeding including upper gastrointestinal …

Aims Guidelines differ in their recommendations on therapy to prevent gastrointestinal
bleeding for patients treated with dual antiplatelet treatment (DAPT). We sought to …

Dual antiplatelet therapy (DAPT) and proton pump inhibitors (PPIs) are widely used in
clinical treatment. However, the pharmacokinetic interaction between PPIs and DAPT is still …

Background Dual antiplatelet therapy (DAPT) is recommended in secondary prevention after
coronary artery bypass grafting (CABG), but it is inevitably associated with the risk of …

Background Proton pump inhibitors (PPI) may decrease the availability of clopidogrel by
competitive antagonism, leading to a potential increase in ischemic events. Methods We …

Objectives: Mitigating the gastrointestinal (GI) bleeding risks of dual antiplatelet therapy
(DAPT) is a common clinical concern. While proton pump inhibitors (PPIs) remain the most …